A bill to amend title 5, United States Code, to include Parkinson's disease in the list of illnesses and diseases deemed to be proximately caused by employment in fire protection activities, and for other purposes.
Summary
S4658 is an early-stage bill to add Parkinson's disease to the list of conditions deemed proximately caused by firefighting employment under federal workers' compensation. It was introduced and referred to committee on June 2, 2026, with no appropriation or mandate. Market impact is negligible.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.S4658 is a narrow workers' compensation eligibility expansion for federal firefighters with Parkinson's disease.
- 2.The bill authorizes no spending and is in the earliest legislative stage.
- 3.No publicly traded companies are directly affected by this procedural bill.
Market Implications
There are no market implications from this bill. It is a narrowly focused workers' compensation classification change with zero authorized funding and no procurement or regulatory mechanism that affects publicly traded companies. Investors should not allocate capital based on this legislation.
Full Analysis
- Senator Banks (R-IN) introduced S4658 on June 2, 2026. The bill was read twice and referred to the Committee on Homeland Security and Governmental Affairs. It is in the earliest legislative stage with only two actions and one cosponsor. 2) The bill contains no funding authorization or appropriation. It would amend 5 U.S.C. to add Parkinson's disease to a list of presumptive conditions for federal firefighters, affecting workers' compensation eligibility under the Federal Employees' Compensation Act (FECA). No direct market-relevant spending is authorized. 3) The bill does not impose mandates, create incentives, or allocate procurement. Any downstream effects on healthcare costs or insurance liabilities are immaterial at this stage. 4) No real market data is provided for analysis. 5) The bill must pass committee, receive a floor vote, and clear the House before becoming law. With a single sponsor and one cosponsor, momentum is low. No companion House bill is mentioned.
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
Executive Order: Promoting Efficiency, Accountability, and Performance in Federal Contracting
Executive Order: Accelerating Medical Treatments for Serious Mental Illness
ADVANCED TECHNOLOGY INTERNATIONAL: $304M Department of Health and Human Services Contract
Protecting Health Care and Lowering Costs Act of 2025
DELL FEDERAL SYSTEMS L.P: $602M Department of Veterans Affairs Contract
Consolidated Appropriations Act, 2026
OPTUM PUBLIC SECTOR SOLUTIONS, INC.: $1.1B Department of Veterans Affairs Contract
Executive Order: Realigning United States Core Childhood Vaccine Recommendations with Best Practices from Peer, Developed Countries
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Realigning United States Core Childhood Vaccine Recommendations with Best Practices from Peer, Developed Countries
This executive order directs the CDC and ACIP to review and potentially update the U.S. childhood vaccine schedule to align with recommendations from peer developed countries, which recommend fewer vaccines. It maintains insurance coverage for all currently available vaccines without cost sharing and emphasizes protecting religious liberty and parental authority.
Promoting Efficiency, Accountability, and Performance in Federal Contracting
This executive order mandates that federal agencies default to using fixed-price contracts for procurement, shifting away from cost-reimbursement models. It requires written justification and senior-level approval for any non-fixed-price contract over certain dollar thresholds (e.g., $10M for most agencies, $100M for the Department of War), and directs agencies to review and renegotiate their 10 largest non-fixed-price contracts within 90 days. The order also tasks OMB with implementation guidance and the Federal Acquisition Regulatory Council with proposing regulatory amendments within 120 days.
Accelerating Medical Treatments for Serious Mental Illness
This executive order directs the FDA to prioritize review and facilitate 'Right to Try' access for psychedelic drugs, including ibogaine compounds, that have received Breakthrough Therapy designation for serious mental illnesses. It also allocates $50 million from HHS to support state programs advancing these treatments and mandates collaboration between HHS, FDA, VA, and the private sector to increase clinical trial participation and data sharing for these drugs. The Attorney General is further directed to expedite rescheduling reviews for approved Schedule I psychedelic substances.